Fully-human Monoclonal Antibodies Against Human EphrinB2 and EphB4 for Use in the Study of Cancer Pathogenesis
Posted Jun 06 2010 5:00pm
Description of Invention: Ephrin receptor tyrosine kinases and their ephrin ligands have been implicated in cancer pathogenesis. Ephrin receptors and ligands affect tumor growth, invasiveness, angiogenesis, and metastasis. Ephrin signaling activities in cancer are complex and are only now beginning to be uncovered.
Researchers at the National Cancer Institute-Frederick, NIH, have developed a set of five fully-human monoclonal antibodies against human Ephrin-B2 and Ephrin type-B receptor 4 ("EphB4"). The antibodies were identified by screening a naïve human antibody phage display library against Ephrin-B2 and EphB4. These human monoclonal antibodies have high affinity and specificity for Ephrin-B2 and EphB4.
Research reagents for in vitro/in vivo investigation of Ephrin receptor and ligand interactions
Targeting reagents for in vivo imaging
Research reagents for protein co-crystallization
High affinity and antigen specificity
Bind both soluble ectodomains and cell surface-expressed molecules
Research Material -- patent protection is not being pursued for this technology
Licensing Status: Available for licensing.
Collaborative Research Opportunity: The Center for Cancer Research Nanobiology Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact John Hewes, Ph.D. at 301-435-3121 or email@example.com for more information. Click here to view the NCI collaborative opportunity announcement.
Portfolios: Cancer Cancer - Diagnostics Cancer - Research Materials
For Additional Information Please Contact: Whitney Hastings NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-451-7337 Fax: 301-402-0220